GO
Loading...

Amgen, Cytokinetics Announce Heart Drug Alliance

Amgen and Cytokinetics announced a collaboration to develop heart failure drugs that could yield smaller Cytokinetics more than $600 million depending on development success.

Symbol
Price
 
Change
%Change
EME
---
CYTK
---

Cytokinetics is receiving an up-front fee of $42 million. In addition, Amgen has purchased nearly 3.5 million shares of Cytokinetics at $9.47 a share, or an aggregate price of about $33 million. Cytokinetics shares closed last Friday at $7.48.

Amgen gained an option to participate in development and commercialization of Cytokinetics' lead drug candidate arising from the heart-failure program, CK-1827452, which recently completed two Phase 1 clinical trials.

Cytokinetics also may receive milestone payments of up to $600 million on CK-1827452 and other products arising from the research as well as royalties, the companies said.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • CNBC's Rick Santelli discusses jobs report, productivity gains and trade promotion authority, with Ed Lazear, Hoover Institute senior fellow.

  • Big names in fast food such as McDonalds and Dunkin Donuts are slowing down on unhealthy additives. "Restaurant Startup" host, Joe Bastianich, discusses what this means for the food industry.

  • CNBC's Sue Herera reports Apple is allowing some companies to test apps on the Apple Watch, Google wants to help consumers save on auto insurance and Costco will stop selling meat with antibiotics.